Archive for May, 2014

Right Turn: A new way to meat your favourite celebrity

Author: Stacey Johnson, 05/30/14

> CCRM’s intrepid communications summer student is back! Erin Sugar gets right to the meat of the issue in today’s Right Turn. Does it leave you hungry for more or salivating with anger? Sometimes, an ordinary encasement of all-beef or pork salami is just not going to cut it. Thankfully, for you or the celebrity…Read more

Update on crowdfunding in the regenerative medicine space

Author: Nick Dragojlovic, 05/26/14

> In a recent post on Signals, David Kent made the case for government-funded clinical trials of autologous stem cell therapies, since the lack of proven commercialization models in this area make it difficult to attract private investment. Another way of financing the clinical translation of stem cell therapies with limited commercialization potential is the…Read more

Right Turn: Expose yourself (or your work)

Author: Lisa Willemse, 05/23/14

> Looking for something to do this weekend? Got something to say or show about stem cells? How about one of following — each of them gives you an opportunity to win and/or gain exposure: Write an essay on “Why I want to go to ISSCR 2014”. Fellow blogger Paul Knoepfler launched this just yesterday…Read more

Update from the Clinic: April

Author: Mark Curtis, 05/22/14

. Welcome to your Update from the Clinic for the month of April. Athersys provides disappointing interim results for its MultiStem® cell therapy in ulcerative colitis patients. Sernova continues to demonstrate safety and biocompatability of its Cell Pouch technology in patients with Type 1 diabetes, with one patient now passed the 180-day mark. StemCells completes…Read more

Data is king

Author: Lisa Willemse, 05/21/14

> I’m not an academic, but I’ve been to many scientific conferences and read many more papers over the past 10 years or so. I know how important data is in research. I also know how important it is in communications (where visits, likes or shares are currency). Strangely, though, I had not considered its…Read more

Right Turn: Prof. Molly Shoichet shares her views on commercialization

Author: Stacey Johnson, 05/16/14

. Last November, I wrote about CCRM’s new Regenerative Medicine Video Network and featured an original video with Dr. Stephen Minger, Chief Scientist, Cellular Sciences GE Healthcare Life Sciences in the UK. If you enjoyed his industry perspective and insights on exciting developments and commercialization in the regenerative medicine field, I think you’ll be equally…Read more

Regenerative Medicine Deal Review: April

Author: Mark Curtis, 05/14/14

. Welcome to your RM deal review for the month of April. There were two notable acquisitions this past month. NeoStem entered into an agreement to acquire California Stem Cell, while Aastrom acquired Sanofi’s regenerative medicine business. Read on to find out more. New York-based NeoStem (NBS) entered into a definitive agreement to purchase California…Read more

Sociology and stem cells: a lesson in natural self-healing and why some of us may be better at it

Author: Holly Wobma, 05/13/14

> I think one of the most universally embraced ideas when people gather together and pontificate about how their relatives or colleagues turned out they way they did, is that ‘people are a product of their environment’. I’m not here to make a singular stand against this notion — in fact, it certainly can explain…Read more

Right Turn: What is aging?

Author: Lisa Willemse, 05/09/14

> I said goodbye to a much beloved uncle this week. I suppose it’s inevitable that mortality, aging and how and when we share our feelings with those we love would be on my mind over the 16 hours of driving to and from the funeral. Also not surprising that this week’s Right Turn would…Read more

Will bone marrow stem cells help heart attack patients? Even cowboy trials have a role to play…

Author: David Kent, 05/06/14

> My last post introduced the large-scale publicly funded clinical trial called BAMI (the effect of intracoronary reinfusion of Bone marrow-derived mononuclear cells on all course mortality in Acute Myocardial Infarction). That post focused on the role of the public purse in funding such trials and concluded that public monies have a major role to…Read more